finanzen.net
12.02.2019 00:05
Bewerten
(0)

Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market

DRUCKEN

NEW YORK, Feb. 11, 2019 /PRNewswire/ -- Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market

Read the full report: https://www.reportlinker.com/p05664243

Summary
Non-Alcoholic Steato-Hepatitis (NASH) is the "silent" liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol, especially people who are middle-aged and overweight or obese. Non-Alcoholic Steato-Hepatitis (NASH) is an advanced form of Non-Alcoholic Fatty Liver Disease (NAFLD). Non-Alcoholic Fatty Liver Disease (NAFLD) is caused by accumulation of fat in the liver. When this also causes inflammation and damage to hepatic cells, it is known as Non-Alcoholic Steato-Hepatitis (NASH), which can lead to scarring of the liver.

Non-Alcoholic Fatty Liver Disease (NAFLD) has become the most common liver disease worldwide. Global prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) is estimated at 24%; the highest rates are in South America and the Middle East, followed by the US and Europe. Non-Alcoholic Fatty Liver Disease (NAFLD) is also an emerging problem in the Asia-Pacific region, where it is likely to increase in the future. Currently, the prevalence population of Non-Alcoholic Fatty Liver Disease (NAFLD) in Asia is around 25%, like many Western countries. Non-Alcoholic Steato-Hepatitis (NASH) is present in at least 20% of obese adults or children and in at least 5% of those who are overweight. The prevalence of Non-Alcoholic Steato-Hepatitis (NASH) in biopsy-proven Non-Alcoholic Fatty Liver Disease (NAFLD) patients is 63.5% in Asia.

The Asia-Pacific (APAC) Non-Alcoholic Steato-Hepatitis (NASH) market is forecast to grow at a compound annual growth rate (CAGR) of 17.2% from 2017 to 2024. Over the forecast period the prevalence of Non-Alcoholic Steato-Hepatitis (NASH) is expected to increase significantly across the APAC markets, in parallel with the increasing prevalence of associated risk factors such as obesity, type II diabetes (T2D), dyslipidemia and other metabolic conditions.

The rising prevalence population, together with the significant diagnostic advancements using ultrasound and biomarkers, improving health awareness, and increasing affordability and healthcare access, will increase diagnosis and the treatment-receiving population, driving demand and contributing to market growth.

Scope
- The NASH Asia-Pacific market will be valued at $102.6m in 2024, growing from $33.7m in 2017 at a CAGR of 17.2%.
- How will the approval of NASH-specific therapies affect the market?
- The NASH market has cheap, generic, off-label drugs, making it a particularly difficult market to penetrate. What are the main barriers a new therapy faces when entering the NASH market?
- How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
- How will changes in risk factors such as population age, obesity, type 2 diabetes, NAFLD, metabolic syndrome and lifestyle influence the market?
- The pipeline for NASH therapies is quite diverse with a range of molecule types and molecular targets.
- Which molecular targets appear most frequently in the pipeline?
- How have the late-stage therapies performed in clinical trials?
- The level of unmet need in the NASH market is significantly high. Will the pipeline drugs fulfill these unmet needs?
- Various drivers and barriers will influence the market over the forecast period.
- Licensing deals are the most common form of strategic alliance in NASH, with total deal values ranging from under $10m to over $300m.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy
This report will enable you to:
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NASH market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the NASH pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NASH market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the NASH deals landscape by analyzing trends in licensing and co-development deals.

Read the full report: https://www.reportlinker.com/p05664243

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/nonalcoholic-steatohepatitis-therapeutics-in-asia-pacific-markets-to-2024---launch-of-nash-specific-premium-products-and-rising-prevalence-to-drive-the-market-300793220.html

SOURCE Reportlinker

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht stark ins Wochenende -- Dow Jones weit im Plus -- Allianz verdient mehr -- EZB senkt Eigenkapitalanforderungen für Commerzbank -- Scout24: Neues Übernahmeangebot -- EDF, Zalando im Fokus

Vapiano enttäuscht mit Umsatz und Ergebnis. Warren Buffetts Depot: Apple-Aktien verkauft. TUI-Chef Joussen kauft für fast 1 Million Euro TUI-Aktien. NVIDIA-Gewinn halbiert - Anleger aber zufrieden. Regierungskrise in Spanien. Applied Materials enttäuscht Anleger mit Umsatzausblick. Möglicherweise Milliarden-Bußgeld gegen Facebook in USA.

Die 5 beliebtesten Top-Rankings

Die korruptesten Länder der Welt
In diesen Staaten ist die Korruption am höchsten
Die beliebtesten Marken im Social Web 2018
Kundenlieblinge 2018
Die teuersten Scheidungen
Diesen Menschen kommt das Liebes-Aus teuer zu stehen
Städte für Millionäre
Hier fühlen sich die Vermögenden am wohlsten
So viel verdienen die reichsten Amerikaner pro Stunde
Wer ist an der Spitze?
mehr Top Rankings

Umfrage

Sind Sie in Cannabis-Aktien investiert?

finanzen.net Brokerage

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Ceconomy St.725750
Wirecard AG747206
Daimler AG710000
Scout24 AGA12DM8
Apple Inc.865985
Amazon906866
Allianz840400
TeslaA1CX3T
CommerzbankCBK100
E.ON SEENAG99
BASFBASF11
BMW AG519000
Deutsche Telekom AG555750
adidasA1EWWW